Who founded Aviceda Therapeutics?

Aviceda Therapeutics was founded by Mohamed Genead, Michael Tolentino, Mohamed A. Genead in 2019.

Who are Aviceda Therapeutics's investors?

Aviceda Therapeutics's investors include Jeito Capital, Longitude Capital, Catalio Capital Management, LP, OrbiMed, Avoro Capital Advisors, Digitalis Ventures, Omega Funds.

How much funding has Aviceda Therapeutics raised?

Aviceda Therapeutics has disclosed $173.6M raised across 7 rounds.

Where is Aviceda Therapeutics headquartered?

Aviceda Therapeutics is headquartered in Cambridge, US.

Aviceda Therapeutics

Cambridge, US · Founded 2019 · Delaware corporation · 18 employees on LinkedIn · 7 known investors

Find your way into Aviceda Therapeutics

Each arrow is one introduction. Sign up to fill in the first one.

340 people can intro you to Michael

Ask Michael Fenn to introduce you to Michael Tolentino

You →Michael · together at Aviceda Therapeutics →Michael

241 people can intro you to Mohamed

Ask Jamie Chen to introduce you to Mohamed Genead

You →Jamie · together at Arionix Therapeutics Inc. →Mohamed

Your email: who you already know at Aviceda Therapeutics, and who your contacts know
2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Aviceda Therapeutics team
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Biotechnology company developing immunomodulators using a HALOS nanotechnology platform for chronic inflammation.

Biotech Digital Health Healthtech Medical Devices

Founders & leadership

Aviceda Therapeutics was founded in 2019 by Mohamed Genead, Michael Tolentino, and Mohamed A. Genead.

Mohamed Genead Co-Founder, CEO & President, Executive Board Director2017–2024Mohamed Genead is a co-founder of multiple biotechnology companies, including Aviceda Therapeutics, and holds an ophthalmology background with clinical expertise. He has served as CEO of Aviceda and co-invented several foundational biotech patents, with experience spanning immunology, cell and gene therapy, and clinical development across oncology and neurology indications.

Michael Tolentino Co-Founder, Senior Scientific Advisor to the CEO2025–2025Michael Tolentino is a retinal surgeon and therapeutic researcher who studied VEGF signaling in macular degeneration and diabetic retinopathy at Harvard Medical School, developed anti-angiogenic and gene therapy approaches at the University of Pennsylvania, and founded or co-founded Aviceda Therapeutics, Aviceda Glycotech, and Avilect Biosciences, serving as chief technology officer and board member across these companies.

Mohamed A. Genead Chairman & CEOMohamed A. Genead is an ophthalmologist and co-founder of multiple biotechnology companies including Aviceda Therapeutics, Aviceda Glytech Ltd, Arionix Therapeutics, and CarThena Therapeutics, with experience in clinical development and business operations across oncology, immunology, fibrosis, and neurology.

David CallananChief Medical Officer2020–2026

Tarek HassanSenior Consultant

Derek KunimotoChief Strategy Officer

Jeffrey NauChief Executive OfficerExecutive Officer, Director at Oyster Point Pharma, Inc.

Tarek S. HassanChief Development Officer

Board

David GuyerBoard director

Nancy ThomasonBoard director

Christoph AdamsBoard director

Erin LavelleBoard director

Investors · 7

Jeito Capital✓ confirmed by Aviceda TherapeuticsParis

How we know: Jeito Capital's portfolio page · the company's own site · funding news · Not right? Tell us

Longitude Capital✓ confirmed by Aviceda TherapeuticsMenlo Park · $10M – $30M

How we know: the company's own site · Longitude Capital's portfolio page · funding news · the VCSheet dataset · Not right? Tell us

Catalio Capital Management, LPlisted by Catalio Capital Management, LPNew York

How we know: Catalio Capital Management, LP's portfolio page · Not right? Tell us

OrbiMedlisted by OrbiMedNew York · $1M – $75M

How we know: OrbiMed's portfolio page · the VCSheet dataset · Not right? Tell us

Avoro Capital AdvisorsreportedNew York

How we know: a partner's Signal profile · Not right? Tell us

Digitalis VenturesreportedNew York · $100K – $10M

How we know: the VCSheet dataset · Not right? Tell us

Omega FundsreportedBoston

How we know: a partner's Signal profile · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$173.6M disclosed across 7 rounds · 2020–2024

▶$75MraisedJan 2025 · 17 investors · Biotechnology

Rule 506(b)